Macfos: Consolidated PAT Up 45% YoY to ₹7.35 Cr as Margins Recover From Q1 Dip
PAT +45.26% YoY · revenue +44.22% · margins expanding
₹98.73 Cr
+44.22% YoY
₹7.35 Cr
+45.26% YoY
7.39%
-0.5pp YoY
₹7.1
Macfos Ltd's consolidated revenue came in at ₹98.73 Cr for Q2 FY27, up 21.4% QoQ and 44.2% YoY, with consolidated PAT of ₹7.35 Cr, up 26.5% QoQ and 45.3% YoY; EPS was ₹7.10 against ₹5.61 in Q1 FY27. There were no exceptional items in either period, and standalone PAT of ₹7.36 Cr is within 1.2% of the consolidated number, so basis makes little practical difference this quarter — the two subsidiaries remain near-dormant. The YoY comparison here uses the Sept-2025 quarter as restated under the Ind AS framework the company adopted voluntarily from 1 April 2026 (₹68.45 Cr revenue, ₹5.06 Cr PAT); our own prior records carry a materially higher 'year-ago quarter' figure (₹127.72 Cr revenue) that lines up almost exactly with this filing's H1 FY26 cumulative total rather than the standalone Q2 FY26 quarter, so that older figure looks mislabeled and has not been used for the growth math above.
Q2 FY-2027 vs prior quarters
Operating margin (profit before tax adjusted for other income and finance cost, over revenue) recovered to roughly 11.8% in Q2 FY27 from about 9.6% in Q1 FY27 — Q1's own commentary had flagged margin softening as the company invested in scaling fulfilment and capability. Net margin held broadly steady near 7.4%. Employee benefit expenses rose 40.3% YoY to ₹4.31 Cr and finance costs rose 74.6% YoY to ₹1.50 Cr as the company kept hiring and borrowing to fund growth. That shows up directly on the balance sheet: consolidated inventory is up 45.7% since FY26-end to ₹115.94 Cr, and current borrowings have nearly doubled to ₹63.12 Cr from ₹35.38 Cr, against a cash balance of just ₹1.54 Cr.
The stock went into the print at ₹1,120, down 0% over the past month of trading.
Management did not provide specific quantitative guidance but expressed confidence in sustaining strong growth, driven by robust demand in the electronics market, which they see as remaining 'hot' for the next few years. The core strategic focus is on maintaining healthy margins through scale advantages and by growing
— This quarter: met
Management gave no quantitative FY27 target on its April 2026 concall, only qualitative confidence in sustaining strong growth in a market it called 'hot,' with margin support expected from the higher-margin 'Robu 2.0' proprietary-product initiative and explicit intent to fund inventory expansion through debt. This quarter's revenue growth, margin recovery and debt-funded inventory build track that framing directly, so the print reads as having met rather than beaten guidance, since no numeric bar was set. No management press release accompanied this specific filing to cross-check against, and no sell-side consensus estimate for this quarter turned up in search — Macfos carries no identified analyst coverage — so the result cannot be benchmarked against a street number this quarter.
W1
Whether operating margin holds near ~11.8% (Q2 FY27) or reverts toward the ~9.6% seen in Q1 FY27 as scale investment continues
W2
Debt-funded inventory build (₹115.94 Cr, +45.7% since FY26-end) against current borrowings of ₹63.12 Cr and cash of just ₹1.54 Cr — watch for working-capital strain if sales conversion lags
W3
Contribution of the 'Robu 2.0' proprietary product initiative, which management (April 2026) targeted for ~10 percentage points higher gross margin than the core business
Converted from ₹ Lacs; no exceptional items, no minority interest (subsidiaries Nuo Zhan Technologies and Macfos Electronics are near-dormant, ~₹12.4 Lakh combined assets, nil/negligible revenue); company voluntarily adopted Ind AS from 1-Apr-2026 and restated the Sept-2025 comparative down to ₹68.45 Cr revenue / ₹5.06 Cr PAT (consolidated) — this is materially different from our DB's stored 'year-ago quarter' figure (revenue ₹127.72 Cr, PAT ₹10.15 Cr), which closely matches this filing's H1 FY26 cumulative total rather than the single Q2 FY26 quarter and appears mislabeled upstream; YoY figures below use the filing's own restated quarterly column, not the DB figure.
H1 growth masks Q2 decline; inventory buildup and margin pressure persist
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
H1 met claimed 41% growth; Q2 missed YoY by 22.7%. Prior guidance vague, new guidance withdrawn.
Neutral
next 1–2 quarters
Cautiously Optimistic
multi-year
H1 growth of 41% revenue is offset by Q2's -22.7% YoY decline, signaling demand weakness in the back half. Inventory has doubled to 120+ days, refund costs spiked 10-fold, and gross margins remain flat despite Robu 2.0 push. Long-term electronics tailwind is credible, but near-term execution is faltering and management is unwilling to commit to specific guidance.
₹181.96 Cr
Revenue · +41% YoY₹13.18 Cr
Reported PAT · +31% YoYFlat
Margins · vs guidance: OverstatedDid the claims hold up?
41% H1 revenue growth; 34% EBITDA, 31% PAT growth
OVERSTATEDQ2 alone -22.7% revenue YoY, -27.6% PAT YoY; H1 growth backloaded to Q1
Gross margins stable, focus on Robu 2.0 margin uplift
MISSGross margin in same line, no improvement. Robu 2.0 <2% revenue, immaterial
Inventory expansion is strategic to serve growing demand
OVERSTATEDDays doubled 60–65 → 120+ due to import costs, financing constraints, not demand
Continued strength and underlying business resilience
MISSQ2 revenue down 22.7%, PAT down 27.6% YoY; refund backlog INR35–40L spiked to INR1.7Cr
Earnings quality
What changed since the last call
Growth guidance withdrawn, numbers now avoided
DowngradeFY-2026 calls promised 'strong growth'; management now refuses to quantify. MD: 'We have decided not to go in that direction, just to keep on putting some numbers.' Signals reduced conviction.
Inventory build-out accelerated; Q1 strong masked Q2 miss
DowngradeH1 +41% growth; Q2 -22.7% YoY. Inventory 120+ days vs. prior 60–65, driven by sea freight economics and financing burden, not demand strength.
Refund/return costs surged; operational backlog disclosed
DowngradeINR1.7Cr return & replacement this quarter (10x prior), vs. INR35–40L 'strategic' backlog. MD expects normalization by Q3 but flagged fulfillment friction.
The Q&A
Analysts pressed on inventory days, gross margins, Robu 2.0 revenue, and cash flow. Management deflected on specifics (won't share mix, won't commit growth numbers), justified inventory with supply-chain costs, and acknowledged margin pressure but claimed it will normalize. Tone defensive; held up poorly to scrutiny on near-term metrics.
Robu 2.0 traction & revenue contribution — Praneeth, SJ Investments
Dodged~310 SKUs in SmartLex, 12–15 in drones, multiple in Pro-Range, EasyMech. <2% revenue. Focusing on market testing, not sharing numbers yet; will disclose when product-market fit proven.
Inventory days explosion — Swaraj Mehta, Perpetual Capital Advisors
PartialInventory days = function of import costs, sea freight, strategic accumulation. Won't share internal targets (public calls, we put out numbers, competitors watch). Expects 120 to stabilize or improve next year.
Gross margin outlook — Swaraj Mehta, Perpetual Capital Advisors
PartialGross margin in same line, no recent change. Want higher margins, but Robu 2.0 still early. Will keep trying different products to improve.
Growth sustainability & capex — Praneeth, SJ Investments
PartialYes, we expect 30–40% growth next 4–5 years. Growing with existing bank financing, no plans for equity raise. Partners are happy to support cash flows.
Competitor impact & market share — Praneeth, SJ Investments
PartialMillennium's model is different (high-volume, manufacturers). RayQ is a distributor (different business). Won't impact Robu's direct model significantly.
Return & replacement cost drivers — Jojo Shaju, Tirthban Capital
AnsweredNothing to do with Robu 2.0. Operational backlog: INR35–40L in unfulfilled refunds. Sea freight backlog, not quality. Will normalize next quarter when backlog clears.
Revenue mix: corporate vs. hobby/startup — Jojo Shaju, Tirthban Capital
DodgedNot sharing breakdown. Corporate segment growing, but we also need starter customers who convert over time. Long-term, more corporate revenue. But small & medium orders both important.
PAT margin sustainability — Praneeth, SJ Investments
AnsweredTargeting 7–8% PAT margin. Won't go below that aggregate. Average order value for corporate is higher, less overhead; so corporate growth actually helps maintain margins.
Supplier payment terms & working capital — Praneeth, SJ Investments
AnsweredYes. Supplier credit terms increasing. Bank relationships strong. Will negotiate better rates as volumes grow. Cost of funds improving gradually.
Robu 2.0 IP moat & competitive sustainability — Rohit, ithoughtPMS
PartialRobu 2.0 is in-house development. Market is expanding (3D printers, drones, wireless, health trackers didn't exist 5–10 years ago). Creating own market, not just taking share.
Migration to mainboard; equity dilution — Rohit, ithoughtPMS
AnsweredNo plans. Equity is costliest money. Prefer to grow via debt and internal cash flows. Only equity as last resort.
Guidance
30–40% growth next 4–5 years; no annual targets
LowManagement explicitly declined to quantify. MD: 'We have decided not to go in that direction.' Vague timeline, no milestones.
7–8% PAT margin floor; gross margin stable
MediumCurrently at 7.4% PAT (in range). Won't go below stated floor. Gross margin unlikely to improve near-term (Robu 2.0 immaterial).
Risks the call surfaced
Demand & growth deceleration
HighQ2 revenue -22.7% YoY despite 41% H1 growth. Suggests demand cliff in H2. Market may be saturating or competitors gaining traction.
Working capital strain; inventory overhang
HighInventory days doubled to 120+ from prior 60–65. Funded by debt ('increasing debt for WC requirements'). If sales don't accelerate, cash conversion will deteriorate further.
Refund/return cost inflation; fulfillment friction
HighReturn & replacement costs spiked to INR1.7Cr (10x prior run-rate). Attributed to operational backlog (INR35–40L unfulfilled refunds). Flags product quality or fulfillment delays.
Margin pressure; Robu 2.0 unproven
MediumGross margin flat despite Robu 2.0 focus. Robu 2.0 <2% revenue, immaterial to margin profile. Higher corporate customer AOV reduces per-unit overhead but doesn't boost gross margin. Long-term margin expansion thesis unproven.
Vague guidance; reduced accountability
MediumManagement explicitly refusing to quantify guidance. MD: 'We have decided not to go in that direction, just to keep on putting some numbers to it.' Signals lower conviction or willingness to be held accountable for commitments.
Management
Score 5/10. Defensive on metrics. Refuses to share revenue mix, growth targets, or margin roadmap. Justifies poor metrics with supply-chain excuses; doesn't own operational issues. H1 delivered 41% growth; Q2 missed YoY by 22.7%. Inventory buildup uncontrolled (60→120 days). Refund backlog (INR35–40L) signals operational missteps. PAT margin stable but not improving.
1 · Q3 FY27
Inventory normalization; refund backlog clearance target
2 · H2 FY27
Robu 2.0 product SKU scaling & revenue contribution disclosure
3 · FY28
Gross margin expansion via proprietary products & tech (if Robu 2.0 gains traction)
Long-term electronics tailwind is credible, but near-term execution is faltering and management is unwilling to commit to specific guidance.
H1 Growth Masks Q2 Demand Cliff; Inventory and Refund Backlog Degrade Earnings Quality
H1 revenue growth of 41% looked strong until the result broke down by quarter: Q2 alone fell 22.7% YoY. Inventory has doubled, refund costs spiked 10-fold, and management stopped guiding. The quarter redefined what's credible about Macfos's near-term story.
₹181.96 Cr
+41% YoY
₹98.7 Cr
−22.7% YoY
₹7.3 Cr
−27.6% YoY
7.4%
stable, not expanding
The headline says Macfos grew 41% in H1. The detail says the company flatlined in Q2. When you strip out Q1's +80% revenue bounce, Q2 revenue contracted 22.7% year-over-year — a demand cliff that no amount of supply-chain narrative can paper over. That misalignment is the story.
What management claimed vs. what the numbers show
41% H1 revenue growth; 34% EBITDA, 31% PAT growth
OverstatedQ2 alone −22.7% revenue YoY, −27.6% PAT YoY. H1 growth backloaded to Q1.
Gross margins stable, focus on Robu 2.0 margin uplift
ContradictedGross margin in same line, no improvement. Robu 2.0 <2% revenue, immaterial.
Inventory expansion is strategic to serve growing demand
OverstatedInventory days doubled 60–65 → 120+ due to import costs, financing constraints. Q2 revenue fell 22.7% YoY (demand-driven buildup, not supply).
Continued strength and underlying business resilience
ContradictedQ2 revenue −22.7%, PAT −27.6% YoY. Refund backlog (₹35–40L unfulfilled) spiked to ₹1.7 Cr total costs.
What changed on this call — the three shifts
1. Guidance was withdrawn, not refreshed. On prior calls, management spoke with confidence about 'strong growth' and a multi-year electronics tailwind. This time, when asked for a growth target, the MD explicitly declined: 'We have decided not to go in that direction, just to keep on putting some numbers to it.' A vague reference to 30–40% growth 'over the next 4–5 years' is not guidance; it's a conversation-ender. The tonal shift from confident to defensive is stark.
2. Inventory buildup was exposed as demand-driven, not supply-driven. Management initially framed the doubling of inventory days (60–65 to 120+) as a calculated bet on sea-freight economics and strategic accumulation. But the Q2 revenue miss (−22.7% YoY) undermines that narrative. If inventory was truly 'strategic' for anticipated demand, Q2 should have been strong, not weak. The inventory is now a working-capital drain financed by debt ('increasing debt for working capital requirements'), with no clear exit.
3. Refund and return costs spiked, flagging operational friction. Return & replacement costs jumped to ₹1.7 Cr this quarter — a 10-fold increase from the prior run-rate of ~₹17 L. Management attributed it to a sea-freight backlog of unfulfilled refunds (₹35–40 L accumulated debt) and said it will 'normalize next quarter.' That promise is credible only if Q3 demand holds and fulfillment catches up. The spike itself signals either quality issues or unfulfilled customer expectations — either way, a deterioration.
Quality of earnings: the working-capital trap
Reported PAT of ₹7.3 Cr (−27.6% YoY) sits at the lower bound of management's 7–8% margin target. But the composition matters. The company is financing an inventory buildup with debt while managing a spike in return costs. Both compress free cash flow. If Q3 demand doesn't reaccelerate, inventory will have to be marked down or warehoused longer, further straining cash. Management's refusal to provide a working-capital guidance or inventory-days target — on grounds that 'competitors watch' — is a missed chance to show conviction. Instead, it reads as evasion.
Robu 2.0: over-promised, under-delivered
Robu 2.0 — the proprietary product suite (SmartLex, drones, Pro-Range, EasyMech) — was positioned as the margin-expansion lever. It is currently <2% of revenue and, per management, still in 'market-testing' mode. Management will 'disclose numbers when product-market fit is proven,' which is another way of saying 'we don't have material traction yet.' Analysts pressed on timeline and SKU mix; management deflected. The long-term case depends on this product reaching 10–20%+ of revenue and carrying higher margins. Today, it's a talking point, not a driver.
Ranked risks — what should concern a holder
1. Demand deceleration; Q2 miss signals sustained weakness
HighQ2 revenue −22.7% YoY despite H1 +41% growth. This is not a seasonal dip; it's a demand cliff. If Q3 remains flat or negative, the inventory buildup will become a cash trap and management credibility will collapse.
2. Working-capital strain; inventory overhang
HighInventory days doubled to 120+, financed by debt. At this level, a 10–15% revenue decline could force a write-down or forced liquidation. Free cash flow will deteriorate before it improves.
3. Refund/return cost inflation and fulfillment friction
HighReturn costs spiked to ₹1.7 Cr (10x prior). If this is a structural shift (product quality or customer expectations unmet), it becomes an operating-margin headwind, not a one-time cost. Management's promise of Q3 normalization is unproven.
4. Margin stagnation; Robu 2.0 unproven
MediumGross margin flat for years. Robu 2.0 immaterial (<2% revenue). Without a clear path to 8–10% gross-margin uplift, the company is stuck at 7–8% PAT and vulnerable to any operating-cost inflation.
5. Management transparency declined; guidance withdrawal
MediumManagement explicitly refused to quantify growth targets or share revenue mix/inventory targets. This reduces accountability and raises the bar for credibility on future calls. Analysts noted defensive tone in Q&A.
How the street is positioned — price action and ownership
The stock is trading at ₹1,051.5, down 24.31% from its all-time high of ₹1,389.25. It sits below both its 20-day (₹1,059) and 50-day (₹1,069) moving averages but above its 200-day (₹1,011), suggesting a slow grind lower without panic selling. Volume is decreasing, which typically reflects fading interest — not conviction in either direction. RSI at 47.8 is neutral; no oversold bounce signal. Ownership has not shifted: promoters hold steady at 69.12%, FII at 0.20% (unchanged), DII at 6.09% (down 0.4pp from Q1). The lack of institutional buying or insider accumulation near these levels suggests the market has not found a compelling entry point.
Valuation context: at a 52-week range of ₹694.6–₹1,315 and now at ₹1,051.5, the stock is in the middle of its range. It's neither a screaming bargain nor a bubble. The -24% drawdown from ATH is noticeable but not yet capitulation-level; it reflects measured repricing as near-term growth has evaporated. For a stock that promised 'strong growth' on prior calls and is now retreating, the price action is rational.
H1 revenue growth of 41% YoY delivered on prior guidance ('strong growth')
Corporate customer base expanding; repeat orders reported healthy
Long-term electronics market tailwind (drones, IoT, automation) real and durable
Scale and supplier relationships are defensible moats
Q2 revenue fell 22.7% YoY; H1 growth masks demand cliff in H2
Inventory days doubled to 120+; working-capital drain funded by debt
Return & replacement costs spiked 10-fold to ₹1.7 Cr; operational friction evident
Gross margin flat for years; Robu 2.0 immaterial (<2% revenue) and unproven
Management withdrew guidance; defensive tone in Q&A; transparency declined
1 · Q3 revenue and demand trajectory
The make-or-break metric. If Q3 revenue stabilizes (minimal growth, no decline), inventory normalization and refund backlog clearance become credible. If Q3 is flat or negative, the company faces a working-capital crisis. This is the number that determines whether Q2 was a one-off or the start of a structural slowdown.
2 · Inventory days and working-capital guidance
Management needs to commit to inventory-day targets (e.g., 'back to 60–75 days by Q4' or similar). Until then, assume inventory is a cash trap. Watch for debt levels, interest expense, and any refinancing announcements.
3 · Robu 2.0 revenue contribution and gross margin composition
The long-term upside hinges on Robu 2.0 reaching 10–20%+ of revenue with 8–10% higher margins. Management needs to disclose SKU mix, sales by product, and gross-margin breakdown by segment. Vagueness here signals lack of confidence or imminent restatement downward.
Macfos is a steady company in a growing market, but this quarter showed the company is not immune to cyclical demand pressure. Q2's 22.7% revenue decline is not a seasonal hiccup; it's a warning that inventory buildup outpaced actual sales, and management had to acknowledge refund backlogs and margin pressure. The withdrawal of guidance and defensive tone in Q&A suggest management is unsure of near-term visibility.
The stock is neither a buy nor a sell at these levels — it's a Hold pending Q3 proof points. The long-term case (corporate adoption, Robu 2.0, market expansion) is intact, but execution risk has spiked. Near-term investors should wait for Q3 demand to stabilize and inventory to normalize. The number to track from here is Q3 revenue — it will settle the debate between those who see a supply-chain detour and those who see demand destruction.